Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
翰思艾泰生物醫藥科技（武漢）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3378)

ANNOUNCEMENT
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FEBRUARY 12, 2026

Reference is made to the circular of Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (the "**Company**") dated January 27, 2026 (the "**Circular**"). Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

The extraordinary general meeting (the "**EGM**") of the Company was held at the Company's conference room at 3/F, Building A8, Phase II of Bio-Innovation Park, No. 1 Jiufeng 1st Road, East Lake New Technology Development Zone, Wuhan City, Hubei Province, the People's Republic of China on Thursday, February 12, 2026 at 10:00 a.m. The proposed resolution as set out in the notice of the EGM dated January 27, 2026 was taken by poll.

The poll results were as follows:

Special Resolution	**Number of Votes (%)**		
	For	**Against**	**Abstain**
To consider and approve the granting of a general mandate to the Board to repurchase H Shares during the Relevant Period.	98,771,940 (99.9996%)	400 (0.0004%)	0 (0.0000%)

Notes:

1. As at the date of the EGM, the issued share capital of the Company comprised 136,218,830 H Shares.

2. The total number of Shares entitling the holder to attend and vote on the resolution at the EGM was 136,218,830 H Shares.

3. There were no restrictions on any Shareholders to cast votes on the resolution at the EGM.

4. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolution at the EGM as set out in Rule 13.40 of the Listing Rules, and no Shareholders were required under the Listing Rules to abstain from voting on the resolution at the EGM.

5. There were no Shareholders that had stated their intention in the Circular to vote against or to abstain from voting on the resolution at the EGM.

6. All Directors have attended the EGM in person or by electronic means.

7. The Company's H Share Registrar, Tricor Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking.

As more than two-thirds of the votes were cast in favour of the resolution, the resolution was duly passed as a special resolution.

By order of the Board
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Dr. ZHANG Faming
Chairman and Executive Director

Hong Kong, February 12, 2026

As at the date of this announcement, the Board comprises (i) Dr. Zhang Faming, Dr. Henry Qixiang Li, Mr. Liu Min and Ms. Xiao Jieyu as executive Directors; (ii) Dr. Li Jian as non-executive Directors; and (iii) Dr. Bi Honggang, Mr. Chen Qifeng, Mr. Wong Sai Hung and Dr. Zhang Qiongguang as independent non-executive Directors.